Patents by Inventor Yuki Miyai

Yuki Miyai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-MEFLIN ANTIBODY FOR USE IN TREATMENT OF CANCER IN SUBJECT HAVING CANCER, AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANTIBODY
    Publication number: 20230084099
    Abstract: An anti-MEFLIN antibody and a pharmaceutical composition comprising the antibody is described. The pharmaceutical composition may comprise an antibody-drug conjugate (ADC) of the anti-MEFLIN antibody and a cytotoxic agent, which may be connected to each other by a linker. The pharmaceutical composition may be used in the treatment of a cancer in a subject.
    Type: Application
    Filed: February 3, 2021
    Publication date: March 16, 2023
    Applicants: National University Corporation Tokai National Higher Education and Research System, Sowakai Medical Foundation
    Inventors: Atsushi ENOMOTO, Nobutoshi ESAKI, Masahide TAKAHASHI, Yuki MIYAI, Ryota ANDO, Yukihiro SHIRAKI, Yoshihiro NISHIDA, Makoto MATSUYAMA, Shino MANABE
  • BIOMARKER FOR PREDICTING EFFECTS OF ANTI-PD-1 ANTIBODY/ANTI-PD-L1 ANTIBODY THERAPY
    Publication number: 20210002714
    Abstract: An object of the present invention is to provide a novel marker that can be used to predict the effect of anti-PD-1 antibody/anti-PD-L1 antibody therapy with high sensitivity, and use thereof. Provided is a biomarker for predicting the effect of anti-PD-1 antibody/anti-PD-L1 antibody therapy, including an immunoglobulin superfamily containing leucine-rich repeat (ISLR).
    Type: Application
    Filed: February 7, 2019
    Publication date: January 7, 2021
    Inventors: Yuki Miyai, Atsushi Enomoto, Masahide Takahashi, Yoshinori Hasegawa, Tetsunari Hase, Yuichi Ando